The kinetics of ribonucleic acid (RNA) and protein synthesis in rifampicin-inhibited normal and ethylenediaminetetraacetic acid (EDTA)-treated Escherichia coli was measured. Approximately 200-fold higher external concentrations of rifampicin were needed to produce a level of inhibition in normal cells comparable to that observed in EDTA-treated cells. The rates of RNA and protein synthesis in both kinds of cells decreased exponentially, after an initial lag phase, at all rifampicin concentrations tested. The lag phase was longer and the final exponential slope less for protein synthesis than for RNA synthesis at a given rifampicin concentration. Below certain rifampicin concentrations, both the lag phase and the subsequent exponential decrease in the rates of RNA and protein synthesis were found to be rifampicin concentration dependent. At greater concentrations only the time of the lag phase was decreased by higher rifampicin concentrations, whereas the slope of the exponential decrease in the rates of RNA and protein synthesis was unaffected. In all cases, the exponential decrease continued to at least a 99.8 % inhibition of the original rate of synthesis. These in vivo results are consistent with the mode of rifampicin action determined from in vitro studies; rifampicin prevents initiations of RNA polymerase on deoxyribonucleic acid, but not its propagation, by binding the enzyme essentially irreversibly. The results also indicate the size distribution of messenger RNA molecules in E. coli under our conditions. During the course of experiments designed to elucidate the nature of ribonucleic acid (RNA) and protein synthesis in phage-infected Escherichia coli cells, we have found, as have others (6, 23) , that E. coli is relatively impermeable to the drug rifampicin. [Rifampicin is 3-(4-methyl-Ipiperazinylimino methyl) rifamycin. Previous names for the same compound were rifaldazine (8, 25) and rimactane (31).] At least two methods of circumventing this problem have been reported: (i) the use of ethylenediaminetetraacetic acid (EDTA) to make cells permeable to rifampicin (6), and (ii) the selection of mutants of Escherichia coli which are permeable to rifampicin [(23), and strain D22 (21) as used by Summers and Siegel (27)]. Since leucine incorporation was drastically reduced in our EDTA-treated cells and since we felt that the use of membrane permeability mutants might complicate our interpretation of experiments involving both rifampicin and phage infection, we chose to examine the possibility that effective intracellular concentrations of rifampicin might be achieved in E. coli K-12 by using high extracellular concentrations. Our results show that high external concentrations of rifampicin inhibit RNA synthesis in normal cells almost as efficiently as 100-fold lower concentrations used on EDTA-treated cells. However, at the same extracellular rifampicin concentration (e.g. 200 ,g/ml), RNA synthesis is inhibited 99% in a shorter period of time in EDTA-treated cells compared to normal cells. As a by-product of our investigation, we found that our in vivo data are consistent with the idea that rifampicin acts in vivo as it does in vitro;
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i.e., rifampicin inhibits the initiation of RNA polymerase on deoxyribonucleic acid (DNA), but not its propagation, by binding the free enzyme essentially irreversibly. In addition, our data, given certain assumptions, indicate the in vivo size distribution of messenger mRNA molecules.
MATERIALS AND METHODS
Bacterial strains. A derivative of strain W3110, obtained from C. Yanofsky, which requires tryptophan and arginine for growth [previously reported as PB 154, trp A36 arg H (7)] was used for all experiments reported here.
Growth conditions. Cells were grown with aeration in M9 medium (1) supplemented with 40 ,ug of arginine per ml, 5 ,ug of leucine per ml, and 20 ,ug of each of 17 other amino acids per ml; threonine was omitted. The doubling time in this medium (35 min at 37 C) was the same as in M9 medium supplemented with 0.25% Casamino Acids.
For experiments, overnight cultures grown at 37 C were diluted 100-fold into fresh prewarmed medium containing 4 ;&g of uridine per ml (or 5 ,ug/ml where specified) and were used during exponential growth at 37 C when the cells had achieved a concentration of 2 X 108/ml. At this concentration of uridine (4 ,g/ml) , almost all pyrimidines in RNA are derived from the medium (4) . The intracellular pool size of uridine should not be affected by the addition of radioactive uridine to medium containing 4 Ag of cold uridine per ml as is the case for uracil (20) .
Addition of rifampicin to growing cultures. When rifampicin was used for in vivo experiments, it was added to exponentially growing cells by mixing one culture volume with an equal volume of prewarmed medium containing rifampicin at twice the desired final concentration. Reagents and chemicals. Rifampicin (a gift of D. J. Galzer, CIBA) was dissolved in water to give a stock solution of 1 mg/ml. Aqueous solutions of rifampicin at this concentration were usually prepared fresh by mixing overnight at 4 C, although they were apparently stable for approximately 5 days. After this time they gradually lost their ability to inhibit uridine incorporation, and thin-layer chromatography (11) revealed a new spot which did not comigrate with rifampicin. Media containing rifampicin was made by using the appropriate amount of rifampicin stock solution in place of water. In this way, it was possible to obtain medium containing 800 ug of rifampicin per ml. Uridine-5-3H (4 Ci/mmole), '4C-L-leucine (312 mCi/mmole), amino acids, and nucleotides were obtained from Schwarz BioResearch Inc., Freehold, N.J. Darco G60 charcoal was obtained from Matheson, Inc., East Rutherford, N.J.
Measurement of RNA and protein synthesis. To assay for acid-insoluble radioactivity in RNA and protein, a 0.2-ml sample of isotope containing culture was mixed with approximately 3 ml of cold 5% trichloroacetic acid and allowed to precipitate at 0 C for at least 15 min. Each sample was then filtered on a Whatman GF/C glass filter washed with approximately 25 ml of cold 5% trichloroacetic acid followed by approximately 10 (20) . Their methods were followed in detail except that GF/C glass filters were used instead of Gelman VM6 filters and high-voltage paper electrophoresis was performed at 0 C for 2.5 hr on 45.7-cm paper strips at 2,500 v. In a second method, 1.0-ml culture samples were added to an equal volume of 10% trichloroacetic acid and allowed to sit in ice for 30 104, 1970 Each sample was then evaporated to dryness and resuspended at 0 C in 10 to 20 ,uliters of water containing standard pyrimidine nucleotides. Such samples were subjected to electrophoresis as described above, and the radioactivity of ultraviolet (UV)-absorbing spots was determined.
RESULTS
Rifampicin inhibition of 3H-uridine and 14CG leucine incorporation. Preliminary experiments showed that strain PB 154 grew normally at 37 C with 1.0 jig of rifampicin per ml in the medium. Growth was inhibited by a rifampicin concentration of 10 Fig. IA, uridine incorporation continues at an undiminished rate in normal cells for 1 min after the addition of rifampicin. After the 1st min, the rate of incorporation slows until the beginning of the 3rd min at which time the amount of acid-precipitable 3H begins to decrease. The decrease in the rate of 3H-uridine incorporation 2 min after the addition of rifampicin and the subsequent decrease in acid-precipitable 3H are not due to a lack of uridine or 3H-uridine in the medium, because we have found that the incorporation of 3H-uridine is linear for 20 min under these conditions. The decrease in acid-precipitable 3H, which begins 3 min after the addition of rifampicin, ends in a plateau (Fig. IA) . Since other results (Fig. 2) indicate that the rate of RNA synthesis is decreasing during the time of the plateau seen in Fig. IA , we believe that the acid-precipitable 3H represented by the plateau is in stable RNA. As Leive (10) showed, the amount of 3H-uracil incorporated into stable RNA in vivo depends upon the length of time E. coli cells are exposed to 3H-uracil; a 2-min exposure to 3H-uracil results in 55 % of the 3H label appearing in stable RNA, and longer exposures result in a higher proportion of 3H label in stable RNA. It is expected, therefore, from Leive A striking result shown in Fig. 1 is that before the addition of rifampicin the rate of 3H-uridine incorporation is the same in normal and EDTAtreated cells, whereas in contrast the incorporation rate of "4C-leucine is drastically reduced in the EDTA-treated cells. We do not know whether the entry of leucine into EDTA-treated cells is limited or whether the incorporation of leucine into protein is reduced by EDTA treatment. We have not examined this further.
Rifampicin inhibition of the rate of RNA and protein synthesis in normal cells with 200 ug of rifampicin per ml. As mentioned above, the data of Fig. 1 do not accurately reflect the time necessary for rifampicin to inhibit RNA synthesis; rather, the data from this type of isotope-accumulation experiment show the time necessary for rifampicin to inhibit the rate of RNA synthesis to a point at which the rate of RNA decay is faster than synthesis. We will now describe a different type of experiment in which the rate of RNA synthesis is measured by short pulses of 3H-uridine at various times after the addition of rifampicin. In the experiment illustrated by Fig.  2 , rifampicin was mixed with a portion of culture to a final concentration of 200 ,ug of rifampicin per ml (see Materials and Methods). At 20-sec intervals thereafter, samples were removed from the rifampicin-containing culture and exposed for 1 min before precipitation with 5% trichloroacetic acid to medium containing 3H-uridine, '4C-leucine, and rifampicin at 200 ,ug/ml. Thus, for any sample this procedure measures the incorporation of label possible in 1 min with rifampicin present, after various periods of exposure to rifampicin alone. A second sample of culture was exposed for 1 min to the isotope-rifampicin mixture without prior exposure to rifampicin and then was precipitated with 5% trichloroacetic acid. In this sample, isotope incorporation occurred for 1 min in the presence of rifampicin, and this is shown as the 1-min point in Fig. 2 . As shown in Fig. 2 , there are three distinguishable phases of incorporation: an initial phase of no change in the rate of incorporation, a second phase of decreasing incorporation rate, and a third phase represented by an exponential decay in the rate of incorporation. The duration of the first two phases of IA, but the duration of each phase is different from that seen for 3H-uridine. In this experiment, as with other experiments that we report of this type, we measured the rate of incorporation by uninhibited cells and found it to be essentially constant over this time period (7 min). This experiment indicates the kinetics of uridine and leucine incorporation in normal cells inhibited by 200 jAg of rifampicin per ml.
Limitations of the experiment shown in Fig. 2 . Since a rifampicin concentration 20-fold higher than that necessary to inhibit growth was required to produce the inhibition shown in Fig. 2 , we felt that this high concentration might interfere with the entry of uridine or the formation of RNA precursors. To examine this possibility, 3H-uridine was added to cells 10 min after the culture was exposed to 200 ,ug of rifampicin per ml, and the intracellular nucleotide pools were examined for the appearance of 3H nucleotides, If rifampicin inhibition of 3H-uridine incorporation into trichloroacetic acid-insoluble material was due to an inhibition of 3H-uridine transport into the cells, then the appearance of 3H in intracellular nucleotides would be reduced. This should be especially true 10 min after the addition of 200 ,ug of rifampicin per ml to a culture, a time at which the rate of 3H-uridine incorporation is inhibited greater than 99% (Fig. 2) . shows the electrophoretic distribution of 3H nucleotides obtained from intracellular pools 15 min after the addition of 3H-uridine to control (Fig. 1A) and to rifampicin-treated (Fig. IB) cells. The distribution of radioactivity in nucleotide samples obtained from rifampicin-treated cells is similar to that obtained from normal cells. Although we have not tried to quantitate these results, it is clear that more RNA precursor nucleotides [cytidine triphosphate (CTP) and UTP] are present in rifampicin-treated cells, relative to uridine diphosphate glucose (UDPG) than in normal cells. Samples obtained 5 and 10 min after the addition of 3H-uridine produced patterns similar to those in Fig. 3 , except that the amount of CTP (as measured by the area under the peak of radioactivity) was less for rifampicintreated cells at 5 and 10 min. The amount of UDPG increased proportionately with increasing time of exposure to 3H-uridine in both control and rifampicin-treated cells. These results indicate that radioactive nucleotide precursors of RNA were present in cells in which RNA synthesis was completely inhibited. Thus, failure to demonstrate 3H-uridine incorporation in rifampicin-inhibited cells is not due to an inhibition of 8H-uridine entry or conversion to nucleotides, but it is due to an inhibition of nucleotide incorporation into nucleic acid polymers.
Estimate of RNA synthesis inhibition from Fig.  2 . We would like to use the 3H-uridine incorporation data in Fig. 2 to estimate the time necessary for this rifampicin concentration to completely inhibit RNA synthesis. However, our data probably do not provide a direct estimate of the time necessary for rifampicin to produce a given level of inhibition in the rate of RNA synthesis for the following reasons. (i) A fraction of the 3H-uridine incorporated into trichloroacetic acid-insoluble material may not be in RNA, thus producing an overestimate. (ii) We might underestimate inhibition time from the data because a fraction of the 3H incorporated into RNA during a 1-min pulse of 3H-uridine is probably in unstable RNA (mRNA) which might decay to acid-soluble material and not be recovered. This underestimate might be increased due to an enhancement of mRNA decay by rifampicin. (iii) The data may provide a drastic underestimate of inhibition time due to a decrease in the specific activity of radioactive precursors in the intracellular pools during pulses of 3H-uridine given after the addition of rifampicin. This could occur as a consequence of radioactive precursors being diluted by nonradioactive mRNA breakdown products and decreased entry of 3H-uridine as RNA synthesis is inhibited. (iv) Inhibition time might be overestimated because our measurements do not provide instantaneous rates but are the average rate over 1 min. We will now consider the factors separately to see how they influence the data of Fig. 4 .
(i) We can estimate the fraction of 3H-uridine incorporated into RNA by experimentally determining the fraction of 3H appearing in trichloroacetic acid-insoluble material which is alkali labile. This fraction, normally 96% of total incorporation under our conditions, changes with time after the addition of rifampicin. Thus, we have determined the fraction of alkali-labile material incorporated in a subsequent experiment.
(ii) If some of the 3H-uridine incorporated into RNA during 1 min is not recovered as trichloroacetic acid-insoluble material due to RNA degradation (such as mRNA decay), then we may be underestimating the time necessary for rifampicin to decelerate RNA synthesis to a given level. According to the results of Leive (10), obtained with a K-12 strain of E. coli, approximately 80% of a short-term uracil pulse appears in labile RNA in vivo. In addition, her results show that approximately 30% of "4C-uracil previously incorporated during a 30-sec pulse becomes acid soluble 1 min after the addition of actinomycin. Assuming her data are applicable to our results and that 100% of 3H-uridine incorporated into RNA in our experiments would be in labile RNA, a maximum of 30% of incorporated 3H-uridine would be degraded. Thus, 30% of the 3H-uridine actually incorporated into RNA in our experiments would not be recovered as trichloroacetic acid-insoluble material. Correcting the data of Fig. 2 by this underestimate increases the time necessary to achieve a 99% inhibition of RNA synthesis by no more than 10 to 15 sec. If rifampicin enhances the destruction of mRNA, the effect on our data is probably small compared to "normal" mRNA decay as the half-life of prelabeled RNA in our experiments (e.g., Fig. 1 ) is approximately 2 min, comparable to that reported by others (10). We will therefore not include a correction of our data for this negligible effect.
(iii) At increasing times after the addition of rifampicin, RNA synthesis is being inhibited, a large fraction of which, as we measure it, is mRNA synthesis (10, 24) . At these times while mRNA synthesis is proceeding at a decreasing rate, mRNA decay is apparently occurring at its normal rate. If a pulse of 3H-uridine is given at these times, the specific activity of radioactive RNA precursors (i.e., 3H-UTP) will be less due to an expansion of the intracellular pools with "cold" RNA precursors derived from decaying mRNA (20) . In addition, since the amount of external uridine entering the cell is apparently (Fig. 2) .
(iv) The minimum time necessary for a given level of inhibition is probably less than that indicated by the data of Fig. 2 . The data points of Fig. 2 a At 4 min before zero time, '4C-uridine (final specific activity, 20 mCi/mmole) was added to a culture growing exponentially at 37 C. The culture was split and at zero time prewarmed medium was added to one-half the culture; rifampicin at a final concentration of 200 ,g/ml was added to the other half. At the listed times, samples were exposed to 3H-uridine (final specific activity, 368 mCi/mmole) for an additional 1 min and then analyzed for 3H and 14C in intracellular nucleotides (see Materials and Methods). Prior to adding isotopes to the medium, the concentration of uridine was 2.5 X 10-M. After the addition of both 14C and 3H uridine, the total concentration of uridine in the medium was 2.7 X 10-5 M. Table 2. synthesis and "4C-leucine incorporation in normal cells, an experiment similar to that in Fig. 2 was performed. In this experiment, however, 3H-uridine and '4C-leucine were added together to measure the rates of incorporation. The rate of 3H incorporation into RNA was estimated by alkali treatment of trichloroacetic acid-insoluble material. The results (Fig. 4) show that the different concentrations of rifampicin generate a family of curves, each curve representing the decay in the rate of RNA synthesis or 14C-leucine incorporation at that particular rifampicin concentration. As in Fig. 2 , there are three phases in the rate of incorporation for each curve. The initial phases are not visible or clearly distinguished for the rate of RNA synthesis at higher concentrations, but all three phases are clearly exhibited by the rate of "4C-leucine incorporation at all four rifampicin concentrations. For each rifampicin concentration, three 1-min incorporation samples were obtained between 21 and 23 min after the addition of rifampicin. The rate of incorporation over this interval for all samples, except '4C-leucine incorporation with 50 ,ug of rifampicin per ml, was equal to or less than 0.2 % We estimated the minimum and maximum times required for all four of the rifampicin concentrations used in Fig. 4 to produce a 99% inhibition in the rate of RNA synthesis (Table 3) . To do this, we assumed that the corrections made for 200 ,g of rifampicin per ml in Fig. 2 can be used directly for the other rifampicin concentrations. This seems reasonable because RNA decay does not appear to be enhanced by rifampicin and it is reasonable to suppose that the specific activity of aH nucleotides in intracellular pools decreases in proportion to the extent of RNA synthesis.
The experiment represented in Fig. 4 shows that the use of 3H-uridine incorporation into trichloroacetic acid-precipitable material as a measure of RNA synthesis produces an overestimate of the time necessary to inhibit the incorporation of 5H-uridine into RNA. If one plots the rate of 3H-uridine incorporation into trichloroacetic acid-precipitable material, instead of alkali-labile aH (RNA) as in Fig. 4 , the same family of curves is obtained. However, the exponential half-life is approximately 10 sec longer and the time necessary to achieve a 99% inhibition of the original rate is between 30 sec and 1 min longer at all rifampicin concentrations (Table 2) . This difference is due to the fact that 3H appearing in alkali-stable material constitutes a larger and larger fraction of total 3H incorporation as inhibition proceeds. Although only 4% of total 3H incorporated appears in alkali-stable material in uninhibited cells and this incorporation is slowly inhibited by rifampicin (at approximately 16% of the rate at which incorporation into RNA is inhibited; unpublished data), this fraction becomes a large proportion of total 3H incorporation as RNA synthesis is inhibited. Thus, rifampicin inhibition of total 3H incorporation is less than the observed inhibition of 3H incorporation into RNA.
Inhibition of protein synthesis in normal cells compared to RNA synthesis. The data of Fig. 4 and Table 2 show that the rate of protein synthesis is inhibited later and decreases more slowly, at all four rifampicin concentrations, than the rate of RNA synthesis. The half-lives for the exponential decay in the rate of '4C-leucine incorporation are less for the three higher rifampicin concentrations (1.2 to 1.4 min; Table 2 ) than the reported value (10) for mRNA decay (1.8 min), whereas the half-life for 50 ,g of rifampicin per ml is longer (2.9 min). At all three higher drug concentrations (100, 200, and 400 jig/ml), it takes approximately 7 min for the rate of protein synthesis to be inhibited 99 % after the rate of RNA synthesis has been inhibited to the same extent (Table 2) . At the lowest concentration of rifampicin tried (50 ,ug/ml), this interval is almost twice as long.
Rifampicin inhibition of the rate of 3H-uridine incorporation by EDTA-treated cells. Experiments like that shown in Fig. 2 were performed on EDTA-treated cells with a range of rifampicin concentrations to determine whether the kinetics of rifampicin inhibition should be the same for EDTA-treated cells as they were for normal cells. Figure 5 shows the effect of high (2 and 200 ,lg/ ml) and low (0.01 to 0.1 jg/ml) rifampicin concentrations on the rate of 3H-uridine incorporation. The high rifampicin concentrations produce an exponential decay in the rate of 8H-uridine incorporation similar to that of Fig. 2 are not visible, a not too surprising result since EDTA treatment reduces the "entry time" of rifampicin (Fig. 1) . Although the slopes of exponential decay are the same for both 2 and 200 ,ug of rifampicin per ml, the slope for the higher concentration is displaced to the left, also indicating, by extrapolation to the initial incorporation rate, that "entry time" is dependent on external drug concentration. The slope of exponential decay seen for 2 Ag of rifampicin per ml has a half-life of 26 sec.
Although a 100-fold increase in rifampicin concentration produces 90% inhibition in a shorter time, a slope with a half-life of 26 sec is still seen. We have consistently seen this half-life of exponential decay in the rate of 3H-uridine incorporation with concentrations of rifampicin greater than 1.0 ,ug/ml. Thus, there is an upper limit to the rate at which 8H-uridine incorporation can be decelerated, whereas "entry" appears to be concentration dependent. A second experiment with low concentrations of rifampicin, also shown in Fig. 5 , reveals four points of interest. (i) After approximately 1 min with no change in the rate, there is a brief stimulation of the rate of 8H-uridine incorporation which is enhanced at lower rifampicin concentrations. (ii) Maximum inhibition is achieved at all four drug concentrations by approximately 6 min, at which time the rate of incorporation begins to increase. (iii) The inhibition of incorporation rates, after the initial stimulation, is qualitatively proportional to drug concentration. (iv) The concentration range of rifampicin at which deceleration becomes noticeably different from the limiting concentration (2 ,ug/ml or higher) spans the concentration reported (2 X 10-8 M) to produce a 50% inhibition of RNA polymerase in vitro (5) . We will call this concentration "Ki."
We have not examined the initial rifampicininduced stimulation in the rate of 3H-uridine incorporation.
As noted in point ii above, there is an apparent recovery from the inhibitory effects of rifampicin in EDTA-treated cells beginning 6 min after the addition of rifampicin (9 min after EDTA treatment). The same recovery phenomenon has been observed for actinomycin inhibition of "4C-uracil incorporation in EDTA-treated E. coli (2, 10) and we have noticed complete recovery from 1.0-,ug rifampicin inhibition of 3H-uracil incorporation in strain PB 154 30 min after EDTA treatment (unpublished data). Since EDTA is eliminated from the medium after EDTA treatment, we presume that the recovery phenomenon is the result of a reestablishment of the normal cell barrier to the entry of rifampicin and to an intracellular inactivation of this drug.
Different rates of decrease in the 8H-uridine incorporation rate are observed at low rifampicin concentrations (Fig. 5) . This is probably not due to intracellular inactivation of rifampicin, because the onset of inhibition occurs at the same time at all rifampicin concentrations and because the quantity of rifampicin in the medium is large (approximately 20,000-fold greater than that present intracellularly, assuming equilibrium) and would not be depleted by the small cellular volume present in these experiments.
Since the range of low rifampicin concentrations in Fig. 5 spans the reported concentration of rifampicin which produces a 50% inhibition of RNA polymerase in vitro, the different inhibition rates after the initial stimulation, but before 6 min, probably represent RNA polymerase inhibition by rifampicin. If the concentration of rifampicin which produces 50% inhibition of RNA polymerase in vitro represents a true Ki in vivo, then one would expect that a plateau of 3H-uridine incorporation rate would be reached which would represent the fraction of uninhibited enzyme. Unfortunately, we are not able to determine whether there is a plateau for any rifampicin concentration due to the recovery from inhibition beginning at 6 min. However, experiments not involving EDTA show that inhibition probably continues below the plateau expected for a given rifampicin concentration, a result which is in agreement with the in vitro results of Wehrli et al. (30) [Half-lives are the same (Table 1 ).] It is, however, a consequence of the time which elapses before exponential decay is achieved. The time before the onset of exponential decay is less for EDTAtreated cells relative to normal cells, probably because of the difference in permeability of these two types of cells to rifampicin. This permeability difference is reflected in the fact that concentrations of rifampicin which produce a 99% inhibition in the rate of 8H-uridine incorporation in EDTA-treated cells have to be increased approximately 200-fold to produce the same effect in normal cells (see reference 2 and last entry in Table 2 ).
As noted in the Results section, a limiting exponential slope is found above certain concentrations of rifampicin. However, below these concentrations (approximately 1 to 2 jig/ml for EDTA-treated cells, approximately 200 ,ig/ml for normal cells), the exponential slope decreases with decreasing rifampicin concentrations. In these "low" rifampicin concentration ranges (0.01 to 0.1 ,ug/ml for EDTA-treated cells, 50 to 200 ,ug/ml for normal cells), the qualitative concentration dependence of the observed slopes could be due either to (i) a concentration-dependent rate of inhibition of RNA synthesis because the internal concentrations of rifampicin are close to the Ki of this inhibitor for RNA polymerase, or (ii) to the fact that the transport of rifampicin across the cell membrane is the limiting step in the observed inhibition. The first alternative would be excluded if it could be shown that the rate of 3H-uridine incorporation was inhibited 99% at concentrations of rifampicin which span the reported in vitro Ki of this inhibitor for RNA polymerase, an observation predicted from in vitro results which show that the binding of rifampicin to RNA polymerase is essentially irreversible (30) . Our experiments with EDTAtreated cells for which rifampicin concentrations in this range were used (Fig. 5) could not have detected a 99% level of inhibition, if it did occur, because recovery from EDTA treatment prevented an accurate determination of the extent of inhibition beyond 6 min after the addition of rifampicin (Fig. 5) . In experiments with normal cells, however, the final level of inhibition obtained in the rate of 3H-uridine incorporation was equal to or greater than 99.8 %. If a change in exponential decay of the rate of 3H-uridine incorporation were due to intracellular rifampicin concentrations close to the Ki of rifampicin for RNA polymerase, one would expect that the rate of incorporation would remain constant at a level of inhibition determined by the intracellular rifampicin concentration relative to the value of Ki. Comparison of Fig. 4 and 5 shows that inhibition by 50 jig of rifampicin per ml for normal cells (Fig. 4) and 0.025 ,ug of rifampicin per ml for EDTA-treated cells (Fig. 5 ) produces decay curves with similar half-lives, presumably reflecting, according to the first alternative, similar intracellular rifampicin concentrations. Since the rifampicin concentration which produces this half-life in EDTA-treated cells is close to the reported Ki (2 x 10-8 M = 0.016 jig/ml), the first alternative would predict that the rate of 3H-uridine incorporation in normal cells should be inhibited by 50 ,ug of rifampicin per ml to a level not less than 40% of the initial rate; alternatively, since the data of the experiment shown in Fig. 5 shows that the level of inhibition is at least 99.8%, it would predict that less than 1% of cellular polymerase molecules are responsible for the normal rate of RNA synthesis. Thus, the first alternative seems highly unlikely, suggesting that (i) the rate of rifampicin transport across the cell membrane is the limiting step in the inhibition of the rate of 3H-uridine incorporation at rifampicin concentrations which are "low" for both EDTA-treated and normal cells, and (ii) the binding of rifampicin to RNA polymerase in vivo is essentially irreversible even at "low" concentrations which produce a time-dependent but complete inhibition of RNA synthesis. This conclusion is consistent with our observation that only 10 ,ug of rifampicin per ml inhibits the growth of normal cells.
Inhibition of RNA polymerase iniitiations in vivo. Our in vivo results are in agreement with those of Lancini and Sartori (9), who used cells of E. coli and Bacillus subtilis to observe that the primary effect of rifampicin was an inhibition of RNA synthesis followed by an inhibition of protein synthesis. Their results showed that 80 jig of rifampicin per ml inhibited '4C-uracil incorporation very quickly after drug addition, a result which has been interpreted to mean that rifampicin inhibits '4C-uracil incorporation almost instantaneously (15) or within 30 sec (28) . However, these investigators observed the quick cessation of '4C-uracil incorporation after a 10-min preincorporation period with '4C-uracil and, therefore, may have been measuring the inhibition of '4C-uracil incorporation into stable RNA. In contrast, our experiments have measured the incorporation of short pulses of 3H-uridine into RNA, a high proportion of which is unstable. Using this method of measurement, we found that inhibition of RNA synthesis by rifampicin is not instantaneous. We found that above certain concentrations of rifampicin (1 to 2 jig/ml for EDTA-treated cells, 200-400 jig/ml for normal cells), a limiting slope is found for the exponential decline in the rate of 3H-uridine incorporation, a slope which is the same (half-life = 26 i 2 sec) for both normal and EDTA-treated cells ( Fig.  4 and 5 Our results with rifampicin contrast dramatically with the inhibition of RNA synthesis obtained in vivo with actinomycin D. Leive (10) reported that actinomycin D shuts off in vivo RNA synthesis in E. coli in less than 15 sec. That in vivo RNA synthesis can be inhibited so quickly is in agreement with in vitro studies which have shown that actinomycin inhibits propagation (13) . Comparison of our results with rifampicin to those obtained with actinomycin D again suggests that rifampicin does not interfere with in vivo RNA polymerase propagation along DNA. It has recently been shown that rifampicin inhibits the initiation of RNA synthesis but not RNA chain growth on the tryptophan operon of E. coli (18) . This same mode of rifampicin action in vivo has also been suggested from results obtained with phage T4-infected cells (22) . Our results are consistent with these observations. Size distribution of mRNA molecules from inhibition kinetics. If we are correct in assuming that rifampicin inhibits RNA synthesis by preventing initiation of synthesis, then we should be able to roughly estimate the distribution of sizes of mRNA. First, however, and hypothetically, consider a large population of cistrons which all have the same length, and assume that the population of RNA polymerase molecules actively transcribing these cistrons are distributed randomly. If an inhibitor is added to this system which prevents further initiations of RNA polymerase molecules but not their propagation, then a linear decrease in transcribing polymerase molecules should result with a concomitant linear decrease in the apparent rate of RNA synthesis. We do not find a linear decrease in the rate of RNA synthesis after adding rifampicin, nor do we expect to, because the size distribution of mRNA in E. coli is heterogeneous (24) . With a heterogeneous size distribution of cistrons, we would expect an exponential decrease in the rate of RNA synthesis if we assume that the probability of finding a polymerase per unit length of DNA is the same on long and short cistrons. In this situation, short cistrons would be the first cistrons (in time) to stop making RNA, whereas long cistrons would continue to make RNA as a consequence of polymerase propagation along their longer length. Thus, the exponential portions of the inhibition curves at high rifampicin concentrations (Fig. 5) should represent the distribution of times necessary to transcribe mRNA molecules. Since the rate of RNA synthesis has been inhibited 99.7 % for the latest time point of 3.6 min in normal cells (400 ,ug of rifampicin per ml; Fig. 4 (17) , is not a common operon size and that longer operons such as the histidine operon with 13,000 nucleotides (3) occur very infrequently.
Inhibition of protein synthesis in normal cells. The rifampicin inhibition kinetics of protein synthesis terminate in an exponential decay of the rate of protein synthesis. As noted in the Results section, the half-life of this exponential decay at 200 and 400 ,ug of rifampicin per ml (Table 1 ) is 1.2 min. Since these two concentrations produce the same slope, which is apparently a limiting decay rate, this value should closely reflect the half-life of mRNA under these conditions. The reported half-life for mRNA in E. coli (12) is slightly longer (1.8 min), perhaps reflecting some RNA synthesis which occurred after the addition of actinomycin D which was used to estimate the disappearance of preincorporated label. That decay of preexisting label in RNA may reflect both synthesis and degradation of RNA after the addition of an RNA synthesis inhibitor may be seen by comparing Fig. 2 and 3 . At the two low rifampicin concentrations (100 and 50 ,ug/ml), the corresponding observed declines in protein synthesis rates may be mainly a function of the decay of the rate of RNA synthesis. That this may be the case is most clearly seen for 50 Mug of rifampicin per ml. In this case, the half-life of decay in the rate of protein synthesis (2.9 min) is longer than the reported half-life for mRNA decay (1.8 min), and the ratio of exponential slopes (protein to RNA) is approximately 2.4, whereas the same ratio is approximately 4.0 for 200 and 400 MAg of rifampicin per ml. For inhibition by 100 Mug of rifampicin per ml, the half-life of decay in the rate of protein synthesis is less (1.4 min) than the half-life of mRNA decay, but the ratio of slopes (protein to RNA) is approximately 2.5, or a value intermediate between that obtained for the higher rifampicin (ratio, 4.0) and the lower rifampicin (ratio, 2.4) concentrations. Thus, for this rifampicin concentration (100 ,ug/ml) the observed decline in the rate of protein synthesis is most probably a function of both mRNA decay and the decline in its synthesis. RNA synthesis is inhibited in normal cells sooner than protein synthesis at all four rifampicin concentrations used (Fig. 4) . The delay in the inhibition of protein synthesis is expected, even if mRNA limits protein synthesis, if most mRNA molecules are degraded in a direction colinear with their synthesis (17) and if protein synthesis initiates at some point distal from the initiation point of RNA synthesis. The rates of decay of RNA and protein synthesis per se are not expected to be related; one reflects the transit time of RNA polymerase molecules, the other the lifetimes of mRNA molecules. What can be said is that the latter is longer than the former so that some mRNA must exist for a period of time after it has been completely synthesized.
